1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Khiron Life Sciences Corp.

Khiron Life Sciences Corp.

KHRNF
Khiron Life Sciences Corp.US flagOther OTC
0.00
USD
- -
- -
2,324.00Market Cap
Khiron Life Sciences Corp.
KHRNF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2017
2018
2019
2020
2021
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
0.02
0.09
0.07
0.08
0.08
Revenue per Share
-0.06
-1.48
-0.49
-0.5
-0.31
-0.24
- -
-0.41
-0.36
-0.2
-0.2
-0.16
Basic EPS, GAAP
-0.02
-0.91
-0.55
-0.42
-0.31
-0.11
- -
-0.38
-0.35
-0.23
-0.13
-0.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.14
1.16
0.21
-0.19
-0.54
-0.78
- -
0.33
0.6
0.44
0.18
0.12
Book Value per Share
0.83
1.66
0.42
0.18
-0.36
-0.57
- -
0.39
0.49
0.37
0.17
0.1
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
28
49
102
120
165
193
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
10
8
13
16
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-2,095.8
-392.18
-294.42
-154.65
-103.27
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
2
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
-20
-36
-24
-33
-31
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-2,221.27
-379.63
-299.85
-258.92
-190
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
17
36
29
16
9
Working Capital
- -
- -
- -
- -
- -
- -
- -
2
3
2
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
26
70
63
33
27
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-134.35
-116.31
- -
- -
- -
- -
-243.92
-93.8
-41.91
-79.8
-84.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
2
1
1
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
180
210
217
Market Capitalization
43
22
19

Working Capital

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
22
22
18
Cash, Cash Equivalents & STI
5
6
2
Accounts Receivable, Net
4
4
4
Inventories
10
9
10
Total Current Liabilities
11
8
10
Payables & Accruals
6
7
7
ST Debt
2
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-47.29%
Free Cash Flow
- -
- -
-18.67%
Net Income, GAAP
- -
- -
37.81%
Sales/Revenue/Turnover
- -
- -
59.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
2
2
2
3
8
2021
3
3
4
4
13
2022
5
4
3
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.08
-0.05
-0.06
- -
-0.2
2021
-0.04
-0.03
-0.02
- -
-0.2
2022
-0.03
-0.01
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Isracann Biosciences Inc. (ISCNF)
Zeria Pharmaceutical Co., Ltd. (4559.T)
Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
Green Hygienics Holdings Inc. (GRYN)
Love Pharma Inc. (LUV.CN)
Shineco, Inc. (TYHT)
Business
Khiron Life Sciences Corp. is a vertically integrated medical and consumer packaged goods cannabis company with core operations in Latin America, primarily Colombia, and expanding operations in Europe and North America. Founded in 2012 and headquartered in Vancouver, Canada, the company focuses on the cultivation, production, domestic distribution, and international export of both high- and low-THC medical cannabis products. Its primary business segments include Medical Cannabis Products, Health Services, and Wellbeing Products. The Medical Cannabis Products segment involves branded cannabis products targeting patients with conditions such as chronic pain, epilepsy, depression, and anxiety. The Health Services segment operates a network of medium complexity health centers and clinics under the Zerenia and ILANS brands, providing integrated medical care, patient education, and telemedicine services. The Wellbeing Products segment develops CBD-based cosmeceutical products under the Kuida brand and offers a range of consumer packaged goods including cosmetics, food, beverages, supplements, and pet care products. Recent major developments include Khiron’s strategic acquisition of Pharmadrug Production GmbH in 2022, which established a European manufacturing and distribution hub that provides direct access to German pharmacies and strengthens its European market presence with higher gross margins. In 2023, Khiron completed the sale of its European subsidiaries including Khiron Europe GmbH and Zerenia UK to align its operational focus. The company commenced a significant contract with Colombia’s largest public insurance provider, Capital Salud EPS, enabling insured patients full reimbursement for medical cannabis treatments at Zerenia clinics. Additionally, the Colombian government mandated insurance coverage for medical cannabis products beginning January 2023, thereby facilitating expanded patient access and revenue predictability. Khiron has launched new cannabis flower products in Switzerland under the KHIRON brand and expanded its product portfolio in Germany and the UK with multiple new SKUs. Training programs for healthcare professionals and real-world clinical evidence presentations support its leadership in medical cannabis education and responsible prescription practices. These strategic moves reinforce Khiron’s positioning as a leading medical cannabis provider with a patient-oriented approach across Latin America and Europe.

Company News

APIChat

  • newsfilecorp.com

    Khiron Life Sciences Announces Closing of the Sale of Its European Business

  • newsfilecorp.com

    Khiron Life Sciences Announces Update to the Proposed Sale of Its European Business

  • headlinesoftoday.com

    KHIRON LIFE SCIENCES ANNOUNCES CEASE TRADE ORDER

  • seekingalpha.com

    Khiron Life Sciences Corp. (KHRNF) Q3 2022 Earnings Call Transcript

  • prnewswire.com

    Khiron to Host Third Quarter 2022 Conference Call on November 30, 2022

  • seekingalpha.com

    Khiron Life Sciences Corp. (KHRNF) Q2 2022 Earnings Call Transcript

  • proactiveinvestors.com

    PharmaDrug closes sale of German cannabis assets to Khiron Life Sciences

  • benzinga.com

    Khiron Life Sciences Raises C$4M Via Equity Offering

  • proactiveinvestors.com

    PharmaDrug agrees to sell German cannabis distribution subsidiary in exchange for equity in Khiron Life Sciences and $1.1M promissory note

  • prnewswire.com

    Khiron to Host First Quarter 2022 Conference Call on May 31, 2022

  • seekingalpha.com

    Khiron Life Sciences' (KHRNF) CEO Alvaro Torres on Q4 2021 Results - Earnings Call Transcript

  • prnewswire.com

    Khiron to Host YE and Fourth Quarter 2021 Conference Call on May 2, 2022

  • prnewswire.com

    Khiron Life Sciences to Present at Upcoming March Investor Conferences

  • prnewswire.com

    Khiron to Participate in the Lytham Partners Winter 2021 Investor Conference

  • seekingalpha.com

    Khiron Life Sciences Corp (KHRNF) CEO Alvaro Torres on Q3 2021 Results - Earnings Call Transcript

  • benzinga.com

    Khiron Life Sciences Q3 Revenue Grows 83% YoY To $2.78M

  • prnewswire.com

    Khiron Life Sciences to Present at Upcoming November Investor Conferences

  • benzinga.com

    Khiron Life Sciences's Study: 80% Positively Respond To Cannabinoid Treatment For Chronic Pain And Other Conditions

  • prnewswire.com

    Khiron presents its first research study with 1,400 patients

  • prnewswire.com

    Khiron reports medical cannabis prescription growth in South America and Europe